Status:
TERMINATED
Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
With Contrast Enhanced UltraSound (CEUS) cancer induced neovascularisation can be visualised with the potential to improve ultrasound imaging for prostate cancer detection and localisation significant...
Eligibility Criteria
Inclusion
- Population:
- All patients already scheduled for biopsy because of a raised Prostate-Specific Antigen (PSA) and/ or abnormal Digital Rectal Examination (DRE) in the Academic Medical Centre (AMC), excluding patients who do meet the exclusion criteria.
- Inclusion criteria:
- age ≥ 18 years
- signed informed consent
- Exclusion criteria:
- Has documented acute prostatitis or urinary tract infections.
- History of any clinically unstable cardiac condition including class III/IV cardiac failure or right-to-left shunts.
- Has had severe cardiac rhythm disorders within the last 7 days.
- Has severe pulmonary hypertension (pulmonary artery pressure \>90 mmHg) or uncontrolled systemic hypertension or respiratory distress syndrome
- Has received a biopsy procedure within 30 days before admission into this study
- Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study.
- Is incapable of understanding the language in which the information for the patient is given.
Exclusion
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT01481441
Start Date
November 1 2011
End Date
November 1 2015
Last Update
July 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AMC University Hospital
Amsterdam, Netherlands, 1105 AZ